Inhibition of osteoporosis by the αvβ3 integrin antagonist of rhodostomin variants

European Journal of Pharmacology

Volumn 804, Issue , 2017, Pages 94-101

  Lin, Tzu Hung ^a,b   Yang, Rong Sen ^a   Tu, Huang Ju ^a   Liou, Houng Chi ^a   Lin, Yen Ming ^c   Chuang, Woie Jer ^d   Fu, Wen Mei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bone mineral density; Bone resorption; Integrin; Osteoclast; Ovariectomy

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DISINTEGRIN; HUMAN SERUM ALBUMIN; OSTEOCLAST DIFFERENTIATION FACTOR; RHODOSTOMIN; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; PEPTIDE; SERUM ALBUMIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOSTEOPOROSIS ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; FEMUR; IC50; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PROTEIN BLOOD LEVEL; RAT; TIBIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; PROTEIN DOMAIN;

ANIMALS; DISINTEGRINS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MUTATION; OLIGOPEPTIDES; OSTEOPOROSIS; PEPTIDES; PROTEIN DOMAINS; RATS; SERUM ALBUMIN;

EID: 85015305027     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.03.019     Document Type: Article

References (18)

1. Boyle, W.J., Simonet, W.S., Lacey, D.L., Osteoclast differentiation and activation. Nature 423:6937 (2003), 337–342.
2. Chambers, T.J., Fuller, K., Darby, J.A., Pringle, J.A., Horton, M.A., Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro. Bone Miner. 1:2 (1986), 127–135.
3. Clover, J., Dodds, R.A., Gowen, M., Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J. Cell Sci. 103:Pt 1 (1992), 267–271.
4. Davies, J., Warwick, J., Totty, N., Philp, R., Helfrich, M., Horton, M., The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J. Cell Biol. 109:4 Pt 1 (1989), 1817–1826.
5. Engleman, V.W., Nickols, G.A., Ross, F.P., Horton, M.A., Griggs, D.W., Settle, S.L., Ruminski, P.G., Teitelbaum, S.L., A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Investig. 99:9 (1997), 2284–2292.
6. Fisher, J.E., Caulfield, M.P., Sato, M., Quartuccio, H.A., Gould, R.J., Garsky, V.M., Rodan, G.A., Rosenblatt, M., Inhibition of osteoclastic bone resorption in vivo by echistatin, an “arginyl-glycyl-aspartyl” (RGD)-containing protein. Endocrinology 132:3 (1993), 1411–1413.
7. Guo, R.T., Chou, L.J., Chen, Y.C., Chen, C.Y., Pari, K., Jen, C.J., Lo, S.J., Huang, S.L., Lee, C.Y., Chang, T.W., Chuang, W.J., Expression in Pichia pastoris and characterization by circular dichroism and NMR of rhodostomin. Proteins 43:4 (2001), 499–508.
8. Horton, M.A., Taylor, M.L., Arnett, T.R., Helfrich, M.H., Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195:2 (1991), 368–375.
9. Kanis, J.A., Diagnosis of osteoporosis. Osteoporos. Int. 7:Suppl. 3 (1997), S108–S116.
10. Lin, T.H., Yang, R.S., Tang, C.H., Lin, C.P., Fu, W.M., PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone 41:4 (2007), 562–574.
11. Lin, T.H., Yang, R.S., Tang, C.H., Wu, M.Y., Fu, W.M., Regulation of the maturation of osteoblasts and osteoclastogenesis by glutamate. Eur. J. Pharmacol. 589:1–3 (2008), 37–44.
12. Lin, T.H., Tang, C.H., Hung, S.Y., Liu, S.H., Lin, Y.M., Fu, W.M., Yang, R.S., Upregulation of heme-oxygenase-1 inhibits the maturation and mineralization of osteoblasts. J. Cell Physiol. 222:3 (2010), 757–768.
13. McHugh, K.P., Hodivala-Dilke, K., Zheng, M.H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F.P., Hynes, R.O., Teitelbaum, S.L., Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Investig. 105:4 (2000), 433–440.
14. Murphy, M.G., Cerchio, K., Stoch, S.A., Gottesdiener, K., Wu, M., Recker, R., Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90:4 (2005), 2022–2028.
15. Nakamura, I., Duong le, T., Rodan, S.B., Rodan, G.A., Involvement of alpha(v)beta3 integrins in osteoclast function. J. Bone Min. Metab. 25:6 (2007), 337–344.
16. Nakamura, I., Tanaka, H., Rodan, G.A., Duong, L.T., Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 139:12 (1998), 5182–5193.
17. Rodan, G.A., Martin, T.J., Therapeutic approaches to bone diseases. Science 289:5484 (2000), 1508–1514.
18. Zhao, H., Kitaura, H., Sands, M.S., Ross, F.P., Teitelbaum, S.L., Novack, D.V., Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J. Bone Miner. Res. 20:12 (2005), 2116–2123.